NVP-BEP800|2mg|K1302-上海高创化学科技有限公司

SKU:K1302		M. Wt:480.41
Formula:C21H23Cl2N5O2S		Solubility:No
Purity:>99%		Storage:2 years at -20 degrees centigrade
CAS No.:847559-80-2		Synonyms:VER-82576
Chemical NameN/A

Description	NVP-BEP800
Targets	HSP90-beta
IC50	58 nM
In vitro	NVP-BEP800 is a novel, fully synthetic, orally bioavailable inhibitor that binds to the NH(2)-terminal ATP-binding pocket of Hsp90. NVP-BEP800 can inhibit HSP90beta with IC50 of 58 nM. NVP-BEP800 showed activity against a panel of human tumor cell lines at nanomolar concentrations. In A375 melanoma and BT-474 breast cancer cell lines, NVP-BEP800 induced client protein degradation (including ErbB2, B-Raf(V600E), Raf-1, and Akt) and Hsp70 induction.
In vivo	NVP-BEP800 showed activity against a panel of primary human xenografts at nanomolar concentrations.Oral administration of NVP-BEP800 was well tolerated and induced robust antitumor responses in tumor xenograft models, including regression in the BT-474 breast cancer model.In these tumor models, NVP-BEP800 modulated Hsp90 client proteins and downstream signaling pathways at doses causing antitumor activity. NVP-BEP800. effectively and specifically killed the majority of primary myeloma cells in coculture with bone marrow stromal cells and reliably entailed molecular consequences of Hsp90 blockade - such as survival pathway breakdown and client protein depletion - in multiple myeloma cells from cell lines as well as from patients.
Clinical Trials	N/A
Features	N/A

Description

NVP-BEP800

Targets

HSP90-beta

IC50

58 nM

In vitro

NVP-BEP800 is a novel, fully synthetic, orally bioavailable inhibitor that binds to the NH(2)-terminal ATP-binding pocket of Hsp90. NVP-BEP800 can inhibit HSP90beta with IC50 of 58 nM. NVP-BEP800 showed activity against a panel of human tumor cell lines at nanomolar concentrations. In A375 melanoma and BT-474 breast cancer cell lines, NVP-BEP800 induced client protein degradation (including ErbB2, B-Raf(V600E), Raf-1, and Akt) and Hsp70 induction.

In vivo

NVP-BEP800 showed activity against a panel of primary human xenografts at nanomolar concentrations.Oral administration of NVP-BEP800 was well tolerated and induced robust antitumor responses in tumor xenograft models, including regression in the BT-474 breast cancer model.In these tumor models, NVP-BEP800 modulated Hsp90 client proteins and downstream signaling pathways at doses causing antitumor activity. NVP-BEP800. effectively and specifically killed the majority of primary myeloma cells in coculture with bone marrow stromal cells and reliably entailed molecular consequences of Hsp90 blockade - such as survival pathway breakdown and client protein depletion - in multiple myeloma cells from cell lines as well as from patients.

Clinical Trials

N/A

Features

N/A

工商信息

企业名称

上海高创化学科技有限公司

企业信息已认证

企业类型

信用代码

310228001353263

成立日期

2010-06-05

注册资本

经营范围

从事化学科技、计算机领域内技术开发、技术咨询、技术服务,从事生物科技领域内技术开发、技术咨询,化学试剂、化工原料及产品(除危险化学品、监控化学品、烟花爆竹、民用爆炸物品、易制毒化学品),实验室设备(除医疗器械),仪器仪表,Ⅰ类医疗器械,金属制品,电子产品,机电产品销售。【依法须经批准的项目,经相关部门批准后方可开展经营活动】

NVP-BEP800由上海高创化学科技有限公司为您提供，货号K1302，规格：2mg，CAS号：847559-80-2，如您想了解更多关于NVP-BEP800价格、NVP-BEP800结构式、批发、用途等信息，欢迎咨询。除供应NVP-BEP800外，还可为您提供大鼠胆囊收缩素/缩胆囊素八肽(CCK-8)ELISA Kit、Gibco马血清（新西兰）、热灭活马血清（新西兰）等试剂，公司有专业的客户服务团队，是您值得信赖的合作伙伴，上海高创客户服务电话，售前、售后均可联系。